8-K ·Filed Apr 20, 2026

NEOG

NEOGEN CORP
NEUTRAL
Impact 3/10
Horizonweeks Processed5mo ago SEC0001193125-26-162667
8-K context-dependent: Items 7.01
Actionable Insight • Neutral

Monitor upcoming earnings reports or regulatory filings for further updates on Petrifilm production scalability or commercial progress. This disclosure is informational and does not indicate near-term financial changes.

DirectionNeutral
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
NEOG ▲ +3.63% at T+60d
NEUTRAL call ✓ call won +3.63% · α vs SPY -3.14% · entry $9.63 → $9.98
Entry anchored
Apr 17, 03:59 PM ET
via exchange tick
T+1d
-2.18%
call -2.18% · α -1.53%
$9.42
settled 5mo ago
T+5d
-1.87%
call -1.87% · α -2.78%
$9.45
settled 5mo ago
T+20d
-11.11%
call -11.11% · α -15.31%
$8.56
settled 5mo ago
T+60d
+3.63%
call +3.63% · α -3.14%
$9.98
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Neogen Corporation disclosed it has completed multiple operational qualifications for certain Petrifilm single kit units (SKUs) and is advancing on performance qualifications as part of its validation efforts. This update was shared ahead of investor tours at its Lansing, Michigan manufacturing facility on April 20 and 21, 2026.

Key Facts

  • Neogen hosted investor tours of its Petrifilm manufacturing facility in Lansing, MI on April 20 and 21, 2026.
  • The company completed multiple operational qualifications for certain Petrifilm SKUs.
  • Neogen is progressing on multiple performance qualifications for these SKUs as part of overall validation efforts.
  • No financial results, guidance, or material business updates were disclosed.

Financial Impact

No immediate financial impact disclosed.

Risk Factors

  • Operational or performance qualifications may not lead to increased production capacity or revenue if scalability challenges persist.
  • Investor interest may be limited without accompanying financial metrics or timeline for commercial impact.

Market Snapshot

Exchange
Nasdaq
Sector
In Vitro & In Vivo Diagnostic Substances

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-162667
Document: 0001193125-26-162667-index-headers.html0001193125-26-162667
Document: 0001193125-26-162667-index.html0001193125-26-162667
Document: 0001193125-26-162667.txt0001193125-26-162667
5 reports for NEOG
Performance horizon
Filters
Rows
Reports for NEOG — sortable, filterable
TypeNow
Aug 21, 2026
6w ago
DEFA14A
NEUTRAL ★ 2/10
$11.95 $13.61▲ +13.89%▲ +14.42%$12.15 (+1.67%)
Aug 7, 2026
8w ago
8-K
NEUTRAL ★ 2/10
$11.40 $11.89▲ +4.25%▲ +5.17%$12.15 (+6.58%)
Jul 30, 2026
9w ago
8-K
MIXED ★ 6/10
$11.53 $11.74▲ +1.82%▼ −2.14%$12.15 (+5.38%)
Apr 20, 2026
23w ago
8-K
NEUTRAL ★ 3/10
$9.63 $8.56▼ −11.11%▼ −15.31%$12.15 (+26.17%)
Apr 9, 2026
25w ago
8-K
MIXED ★ 6/10
$10.04 $9.18▼ −8.57%▼ −16.13%$12.15 (+21.02%)
Showing 5 of 5

US Market Status

Market Closed — Opens Mon (38h 33m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access